Phuturdex › Diseases › Hemic and lymphatic diseases
Drugs in development · updated 9 November 2026
Hemic and lymphatic diseases: drugs in development
What it is
Hematologic diseases and diseases of the lymphatic system collectively. Hemic diseases include disorders involving the formed elements (e.g., ERYTHROCYTE AGGREGATION, INTRAVASCULAR) and chemical components (e.g., BLOOD PROTEIN DISORDERS); lymphatic diseases include disorders relating to lymph, lymph nodes, and lymphocytes.
Source: NLM MeSH (U.S. National Library of Medicine), descriptor D006425, meshb.nlm.nih.gov · public domain · downloaded on 9 November 2026.
As of 9 November 2026 there are 3,502 active clinical trials (recruiting or ongoing, phases I–III) on 1,358 drugs for hemic and lymphatic diseases. 870 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 9 November 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 870 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 436 | NCT04799275 |
| VenetoclaxVentoclax, veneclax | II–III | 347 | NCT03984448 |
| DexamethasoneDexametasone, dexamethsone | II–III | 325 | NCT07570173 |
| RituximabRuxience, Rituxan | II–III | 313 | NCT07917754 |
| FludarabineFludara, FLUDARABIN | II–III | 272 | NCT01949129 |
| LenalidomideRevlimid, Lenalidomide Mylan® | II–III | 246 | NCT07917754 |
| AzacitidineAzacytidine, 5-azacytidine | II–III | 210 | NCT04799275 |
| CytarabineAra-C, Cytosine Arabinoside | II–III | 196 | NCT07255872 |
| PrednisoneCortancyl, Predinisone | II–III | 147 | NCT04799275 |
| DaratumumabDarzalex | II–III | 144 | NCT07887984 |
| DoxorubicinAdriamycin, Doxorubincin | II–III | 144 | NCT04799275 |
| VincristineVincristin, Oncovin [vincristine] | II–III | 137 | NCT04799275 |
| ObinutuzumabGazyva®, Gazyvaro® | II–III | 129 | NCT07724457 |
| BortezomibVelcade, Bortezomib Hospira® | II–III | 114 | NCT07887984 |
| ZanubrutinibZaunbrutinib, BGB-3111 | III | 98 | NCT05976763 |
Sorted by most advanced phase and number of active trials. Showing 15 of 488 drugs.
All 1,358 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Acute myeloid leukemia 301 drugs
- Multiple myeloma 270 drugs
- Diffuse large B-cell lymphoma 178 drugs
- Myelodysplastic Syndromes 223 drugs
- Lymphoma 606 drugs
- Non-Hodgkin lymphoma 507 drugs
- Chronic lymphocytic leukemia 134 drugs
- Precursor lymphoblastic lymphoma/leukemia 169 drugs
- Follicular lymphoma 143 drugs
- Hematologic neoplasm 257 drugs
- B-cell lymphoma 305 drugs
- Mantle cell lymphoma 107 drugs
Broader categories
- Immune System Diseases 1,554 drugs
- Lymphoproliferative disorders 822 drugs
- Immunoproliferative disorder 811 drugs
- Kidney disease 620 drugs
- Urologic Diseases 785 drugs
- Female urogenital disease 1,224 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 9 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006425 “Hemic and Lymphatic Diseases”.